Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anja Reuter

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Tropical Medicine and Infectious Disease|February 24, 2022
Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South AfricaAnja Reuter, Buci Beko, Boniwe Memani, et al.
AIDS (London, England)|July 14, 2015
Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomesViviane D Lima, Anja Reuter, P Richard Harrigan, et al.
The European Respiratory Journal|May 31, 2020
Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?Norbert Ndjeka, Francesca Conradie, Graeme Meintjes, et al.
The European Respiratory Journal|July 25, 2020
Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa"Erika Mohr-Holland, Anja Reuter, Jennifer Hughes, et al.
Nature Reviews. Disease Primers|March 25, 2024
Multidrug-resistant tuberculosisKeertan Dheda, Fuad Mirzayev, Daniela Maria Cirillo, et al.
Open Forum Infectious Diseases|March 13, 2023
Tuberculosis Diagnosis and Preventive Monotherapy Among Children and Adolescents Exposed to Rifampicin-Resistant Tuberculosis in the HouseholdIvy Apolisi, Helen Cox, Nolitha Tyeku, et al.
The Lancet. Infectious Diseases|May 5, 2022
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort studyNorbert Ndjeka, Jonathon R Campbell, Graeme Meintjes, et al.
American Journal of Respiratory and Critical Care Medicine|June 5, 2023
Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant TuberculosisSayalee Patankar, Andrea T Cruz, Bianca Douglas-Jones, et al.
The Lancet. Microbe|June 9, 2023
Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology studyGalo A Goig, Fabrizio Menardo, Zubeida Salaam-Dreyer, et al.
The Lancet. Respiratory Medicine|March 26, 2022
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South AfricaIvy Apolisi, Nandipha Mema, Nolitha Tyeku, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Tropical Medicine and Infectious Disease|February 24, 2022
Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South AfricaAnja Reuter, Buci Beko, Boniwe Memani, et al.
AIDS (London, England)|July 14, 2015
Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomesViviane D Lima, Anja Reuter, P Richard Harrigan, et al.
The European Respiratory Journal|May 31, 2020
Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?Norbert Ndjeka, Francesca Conradie, Graeme Meintjes, et al.
The European Respiratory Journal|July 25, 2020
Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa"Erika Mohr-Holland, Anja Reuter, Jennifer Hughes, et al.
Nature Reviews. Disease Primers|March 25, 2024
Multidrug-resistant tuberculosisKeertan Dheda, Fuad Mirzayev, Daniela Maria Cirillo, et al.
Open Forum Infectious Diseases|March 13, 2023
Tuberculosis Diagnosis and Preventive Monotherapy Among Children and Adolescents Exposed to Rifampicin-Resistant Tuberculosis in the HouseholdIvy Apolisi, Helen Cox, Nolitha Tyeku, et al.
The Lancet. Infectious Diseases|May 5, 2022
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort studyNorbert Ndjeka, Jonathon R Campbell, Graeme Meintjes, et al.
American Journal of Respiratory and Critical Care Medicine|June 5, 2023
Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant TuberculosisSayalee Patankar, Andrea T Cruz, Bianca Douglas-Jones, et al.
The Lancet. Microbe|June 9, 2023
Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology studyGalo A Goig, Fabrizio Menardo, Zubeida Salaam-Dreyer, et al.
The Lancet. Respiratory Medicine|March 26, 2022
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South AfricaIvy Apolisi, Nandipha Mema, Nolitha Tyeku, et al.
Pageof 4